neoIM is the first-in-class immunogenicity predictor with high accuracy in identifying which neoantigens are capable of eliciting a T-cell response. Unlike traditional tools that focus mainly on MHC binding, neoIM directly models immunogenicity and significantly outperforms existing approaches in benchmark datasets and experimental validation.

Key results:

• Achieves up to 30% higher precision than existing predictors in ELISpot assays
• Enables identification of up to 50% more clinically actionable neoantigens for vaccine design
• Demonstrates potential as biomarker, with higher neoIM scores correlating with improved survivial in melanoma patients treated with checkpoint inhibitors